Leukemia Research
Volume 34, Issue 9 , Pages 1111-1118, September 2010

Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma

  • Sundar Jagannath

      Affiliations

    • St Vincent's Catholic Medical Center, 325 W. 15th Street, New York, NY 10011-8202, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 212 604 6068; fax: +1 212 604 6029.
    • ,
  • Meletios A. Dimopoulos

      Affiliations

    • Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece
    • ,
  • Sagar Lonial

      Affiliations

    • Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA

Received 9 September 2009; received in revised form 1 April 2010; accepted 4 April 2010. published online 07 March 2011.

Abstract 

Multiple myeloma (MM) is an incurable disease characterized by the accumulation of malignant plasma cells in the bone marrow. Recently, an improved understanding of the biology of the disease has led to the development of targeted agents such as the proteasome inhibitor bortezomib and the immunomodulatory agents thalidomide and lenalidomide; however, MM remains incurable. The combination of bortezomib and an HDAC inhibitor synergistically induces MM cell apoptosis and may be of value in the treatment of patients with relapsed/refractory MM. This review examines the potential of combined proteasome and HDAC inhibition in the treatment of relapsed/refractory MM.

Keywords: Vorinostat, Multiple myeloma, Histone deacetylase inhibitor, Proteasome inhibitor, Bortezomib

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0145-2126(10)00203-1

doi:10.1016/j.leukres.2010.04.001

Leukemia Research
Volume 34, Issue 9 , Pages 1111-1118, September 2010

Article Tools

* Image Usage & Resolution